Clinical outcome of adjunctive topiramate treatment in a sample of refractory bipolar patients with comorbid conditions.

Author: Guille C, Sachs G

Author affiliation: Harvard Bipolar Research Program, Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA.

Publication date & source: 2002.10, Prog Neuropsychopharmacol Biol Psychiatry., 26(6):1035-9.

Publication type: Research Support, Non-U.S. Gov't

Topiramate, a novel antiepileptic agent, has shown promise in the treatment of bipolar disorder. Patients attending a bipolar specialty clinic and treated with topiramate were identified by chart review, and data were harvested from systematic prospective assessments used routinely in the clinic. Fourteen patients who received topiramate for an average of 22.4 weeks were identified. All but one of these patients were considered to be highly refractory to standard treatment and 13 met the criteria for at least one comorbid psychiatric condition. Nine of these patients (64%) experienced an increased level of functioning and decrease in symptom severity during treatment with adjunctive topiramate. Eleven patients remained on treatment for longer than 2 weeks. Eight of these patients (73%) experienced a significant improvement in their comorbid conditions. Patients with a body mass index (BMI) of > or = 28 (n = 4) experienced a mean weight loss of 29.7 lb while on topiramate. Topiramate appears to be a promising agent for the treatment of bipolar disorder associated with comorbid psychiatric conditions and obesity.